Transmucosal Drug Delivery Devices Market Size Report, Industry Share, Analysis, Growth, 2030

Transmucosal Drug Delivery Devices Industry Prospective:

The global Transmucosal Drug Delivery Devices Market size was worth around USD 41.2 billion in 2022 and is predicted to grow to around USD 68.1 billion by 2030 with a compound annual growth rate (CAGR) of roughly 6.5% between 2023 and 2030.

Request Free Sample

The report analyzes the global Transmucosal Drug Delivery Devices market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the transmucosal drug delivery devices industry.           

Transmucosal Drug Delivery Devices Market: Overview

For therapeutic reasons, transdermal drug delivery systems—an alternative to oral intravascular, subcutaneous, and transmucosal routes—transmit drugs through the skin. For businesses involved in its value chain, the transmucosal drug delivery system offers several advantages over traditional drug administration methods. The ability to avoid the body's inherent defense systems is one of the most important advantages of transmucosal medicine delivery. Due to a sizable target market that would need frequent drug delivery devices for diagnosis and treatment, the transmucosal drug delivery devices market is anticipated to expand in years to come.

Key Insights

• As per the analysis shared by our research analyst, the global Transmucosal Drug Delivery Devices market is estimated to grow annually at a CAGR of around 6.5% over the forecast period (2023-2030).
• In terms of revenue, the global Transmucosal Drug Delivery Devices market size was valued at around USD 41.2 billion in 2022 and is projected to reach USD 68.1 billion, by 2030.
• The global Transmucosal Drug Delivery Devices market is being driven by the increasing prevalence of chronic diseases including cancer and cardiovascular disease.
• Based on the product type, the buccal route segment is expected to dominate the market over the forecast period.
• Based on the application, the hospital segment is expected to capture a significant market share over the forecast period.
• Based on region, North America is expected to dominate the market over the forecast period.

Request Free Sample

Transmucosal Drug Delivery Devices Market: Growth Drivers

The growing prevalence of chronic disease drives the market growth

The growing prevalence of chronic diseases such as cancer, cardiovascular, diabetes, and others are expected to propel the global transmucosal drug delivery devices market over the forecast period. For instance, according to the data provided by Cancer Research UK, if incidence remains steady and population growth & aging continue at current rates, there will be 28 million new cancer cases globally each year by 2040.

This is a 54.9% increase over 2020 and is predicted to be larger in males (60.6% increase) than in females (48.8% increase). Similarly, according to the National Institute of Health figure, diabetes is expected to affect 9.3% (463 million people) of the global population in 2019, increasing to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. The frequency is greater in cities (10.8%) than in rural regions (7.2%) and in high-income nations (10.4%) than in low-income countries (4.0%). Thus, the aforementioned facts support the market revenue growth.

Transmucosal Drug Delivery Devices Market: Restraints

Regulatory and limited drug compatibility hamper the market growth

Due to strict regulatory norms, the development and licensing procedure for transmucosal medication delivery devices can be complicated and time-consuming. Companies in this transmucosal drug delivery devices industry may encounter difficulties adhering to the requirements of numerous health authorities and guaranteeing safety and efficacy.

In addition, devices for transmucosal drug administration might not be appropriate for all prescription drugs. Some medications may not be suitable for absorption through mucosal membranes or may irritate or harm tissues, which restricts their usage with these delivery methods. Thus, this is expected to act as a major restraint for the market growth over the forecast period.

Transmucosal Drug Delivery Devices Market: Opportunities

Increasing collaboration offers a lucrative opportunity for the market growth

The increasing collaboration among the market players to enhance its position in the drug delivery devices industry is expected to offer a lucrative opportunity for market revenue growth over the forecast period. For instance, in December 2022, the conclusion of the merger of the two businesses was announced by Kindeva Drug Delivery and Meridian Medical Technologies. A top worldwide contract development and manufacturing organization ("CDMO") specializing in drug-device combo products have been produced as a result of the combination.

The combined company will do business as Kindeva, with Meridian doing business as "Meridian Medical Technologies, a Kindeva Company". With experience and technology covering the parenteral, inhalation, transdermal, and intradermal modes of administration, the new Kindeva will offer a wider variety of drug delivery capabilities. The merger of Kindeva and Meridian establishes a certain market leader in the CDMO industry for drugs and devices. The expanded scope and selection of medication delivery options will be advantageous to their clients.

Transmucosal Drug Delivery Devices Market: Challenges

High cost and limited drug formulations

Transmucosal drug delivery device development and production can be expensive, especially for small and medium-sized businesses. The transmucosal drug delivery devices market expansion may be hampered by the costs associated with research, development, clinical trials, and production. Moreover, due to their chemical properties, stability issues, or dosage needs, several medication formulations might not be appropriate for transmucosal administration. The variety of medications that can be efficiently given using these devices may be constrained by this limitation.

Transmucosal Drug Delivery Devices Market: Segmentation

The global Transmucosal Drug Delivery Devices industry is segmented based on product type, application, and region.

Based on the product type, the global market is bifurcated into the buccal route, rectal route, and nasal route. The buccal route segment is expected to dominate the market over the forecast period. Buccal medication delivery systems have a very high potential for expansion as a result of ongoing research and development in this area. Buccal administration is seen as more practical and desirable than oral dosing form, particularly among elderly individuals.

This method of drug delivery guarantees the removal of first-pass metabolism, enabling the efficient administration of medicines that are pH sensitive and readily destroyed. Buccal drug administration has become more popular, which is attributed to several benefits, including faster absorption, lower biofluid interaction, fewer adverse effects, high concentration availability at the target location, and shorter treatment regimens. Thereby, driving the segment growth during the forecast period.

Based on the application, the transmucosal drug delivery devices industry is segmented into hospital and residential. The hospital segment is expected to capture a significant market share over the forecast period. The reasons for this segment's expansion include an increase in hospital admissions, particularly of geriatric patients, an excess of emergency care supplies, and product creation and research by several community hospitals. Studies carried out by various hospitals provide innovation and enhance the formulation's commercial viability.

To create mucoadhesive microparticle-laden gels for oral mucositis, for instance, three community hospitals in Japan conducted in vitro and in vivo experiments in 2020. The outcome shows that the rapid treatment compared to conventional dose forms and high concentration of the medicine at the target location are likely to increase adoption. Numerous hospitals in high-income countries are also engaged in the research and development of buccal mucoadhesive formulations that contain insulin, strong analgesics, and medications for the treatment of heart failure. Therefore, this is expected to propel the segment growth over the forecast period.

Transmucosal Drug Delivery Devices Market: Report Scope

 Transmucosal Drug Delivery Devices Market: Regional Analysis 

North America is expected to dominate the market over the forecast period

North America is expected to dominate the global transmucosal drug delivery devices market over the forecast period. The regional growth is ascribed to the growing prevalence of chronic disease along with the increasing geriatric population and the rising regulatory approvals. For instance, according to the National Institutes of Health, between 2020 and 2050, there will be a 61.11% increase in the number of Americans aged 50 and older, from 137.25 million to 221.13 million.

There will be 142.66 million people aged 50 and older in 2050 who have at least one chronic condition, up from 71.522 million in 2020, a 99.5% rise. Moreover, approximately 25% of persons in the US have two or more chronic illnesses, according to statistics from the International Journal of Environmental Research and Public Health (IJEPH). Age affects the prevalence of chronic diseases, and older persons are statistically more likely to have several chronic diseases. It is believed that age and lifestyle modifications both contribute to the elevated risks. Therefore, the aforementioned stats drive the market growth over the forecast period.

Transmucosal Drug Delivery Devices Market: Competitive Analysis

The global Transmucosal Drug Delivery Devices market is dominated by players like:

• Abbott
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Slan Medicinal Holdings LTD
• MMB Healthcare LLC.
• BioDelivery Sciences International Inc.
• Mylan N.V.
• Novartis AG
• Bristol-Myers Squibb Company
• Johnson & Johnson Private Limited
• Antares Pharma
• BD
• 3M
• Pfizer Inc.
• Boehringer Ingelheim International GmbH
• Endo International plc
• Echo Pharmaceuticals B.V.
• B. Braun Melsungen AG
• Baxter
• GlaxoSmithKline plc
• Acrux Limited

The global Transmucosal Drug Delivery Devices market is segmented as follows:

By Product Type

• Buccal Route
• Rectal Route
• Nasal Route

By Application

• Hospital
• Residential

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa